



Contacts: Meg McGilley
Chief Financial Officer
(858) 480-0402

Rob Whetstone
PondelWilkinson, Inc.
(310) 279-5963

Somaxon Pharmaceuticals to Present at the BIOCOM San Diego Investor Conference and 2006 Credit Suisse Healthcare Conference

SAN DIEGO, CA – November 13, 2006 – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will present at the following two conferences:

BIOCOM San Diego Investor Conference

Wednesday, November 15, 2006, at 11:40 a.m. PT (2:40 p.m. ET)

Presenter: Ken Cohen, President and Chief Executive Officer

San Diego Marriott Del Mar, San Diego, CA

2006 Credit Suisse Healthcare Conference

Friday, November 17, 2006, at 9:30 a.m. PT (12:30 p.m. ET)

Presenter: Ken Cohen, President and Chief Executive Officer

Arizona Biltmore Resort, Phoenix, AZ

A live webcast of the presentations will be available in the Investor Relations section of the company's website under Event Scheduler at www.somaxon.com. The webcasts will be archived and accessible for at least 14 days.

About Somaxon Pharmaceuticals

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product candidate, SILENOR™ (doxepin HCl), is in Phase 3 clinical trials for the treatment of insomnia. Nalmefene HCl is in a Phase 2/3 clinical trial for pathological gambling and has completed a pilot Phase 2 trial for smoking cessation.

(more)

Somaxon Pharmaceuticals, Inc.
2-2-2

Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development.

For more information, please visit the company's web site at www.somaxon.com.

#